

“ALSTDF has conducted a very valuable program to screen candidate ALS drugs in ALS mice. At its best, this sort of program achieves two important goals: it tests for compounds that may prove therapeutic in ALS patients and it also probes the biology of ALS as a disease process. Both activities are an essential component of winning the battle against ALS.”

ROBERT H. BROWN, JR., M.D., D.PHIL.



Director of the Day Neuromuscular Research Laboratory and Muscular Dystrophy Association clinic at the Massachusetts General Hospital and Professor of Neurology, Harvard Medical School



215 First Street, Cambridge, Massachusetts 02142

TEL: 617.441.7200 FAX: 617.441.7299

EMAIL: info@als.net WEB: www.als.net



ABOUT ALS

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal neurological disorder that causes muscle atrophy, paralysis, and respiratory failure. ALS has no prejudice – it occurs worldwide, with no age, ethnic, or economic boundaries.

30,000 Americans have ALS today. Up to 8,000 new cases are diagnosed in the U.S. each year. 90% of patients die within 5 years of diagnosis. There is no known treatment or cure.

Dear Friends and Family of ALSTDF:

Six years ago I beat my younger and larger brother Stephen arm wrestling – for the first time in ten years. This was his first symptom and a year and a half later Stephen was diagnosed with ALS.

Today my brother would physically remind you of Stephen Hawking. He uses a computer to talk and drives his wheelchair with buttons mounted on the headrest. He is 34 years old and unable to feed or care for himself.

Why haven't we cured this disease?

Our current scientific system has generated amazing advances in science and continuously generates novel ideas and new knowledge. This process has created our entire existing body of scientific literature. However, I am not sure that having an army of independently motivated scientists – scientists that do small scale projects selected by committee review, projects without coordination or follow up – is the best way to cure a disease like ALS.

The quest for a way that strategically addresses the lack of treatments Stephen and all ALS patients face led to the formation of ALSTDF in April of 1999. As our fledgling R&D team began to strategize about the most effective way to treat ALS, we were greeted by a fertile ground of advances made by world-class researchers, while simultaneously discovering an enormous information and development gap. It was as if the government and charities of the world had planted orchard after orchard brimming with scientific discoveries and not bothered to harvest the fruit.

We do it differently.

At ALSTDF, we began to collect all of the information. Trials, animal studies, drugs in development, biomarkers, theories, opportunities – and four years later, ALSTDF is now an integrated team of professional scientist and drug development experts working each day through emerging data to strategically advance the most promising ideas to patients.

We operate our laboratory like a factory. Instead of solely focusing on one potential therapy, we research multiple pathways of halting the disease and concurrently test as many plausible avenues as our facilities and funds allow.



James Allen Heywood, d'Arbeloff Founding Director

What this means is that we scan all literature and collaborate with leaders in a variety of fields to generate targets for drugs and therapies. We use this information to select and then test drugs in our laboratory on a mouse model of ALS. And our approach is working – as you can see in this annual report, we have made significant strides toward treatments for ALS and are moving forward drugs discovered in our lab into the clinics.

Envision a new future.

Envision a future where strategic plans to effectively treat disease and improve human health are built and implemented without regard to profit or publication. Where we mine the vast scientific knowledge we have compiled and build large-scale programs to deliver tangible improvements in human health. It's not about not require new science or technology. It's about good strategic planning, effective use and investigation of existing knowledge, and execution at a scale that can succeed.

Thank you for helping us build the Foundation that is working to build that future for Stephen and all people affected with ALS. The accomplishments of this year belong to you our supporters and the patients we work for. Help us finish the task and continue to harvest the orchard of scientific ideas until we slow, arrest, and cure ALS.

Thank you,

James Allen Heywood, d'Arbeloff Founding Director

ALSTDF 2002 HIGHLIGHTS

Research & Development (R&D) Highlights 2002

- ▶ Advanced the first potential new treatment discovered in ALSTDF's internal R&D program towards clinical study in ALS patients (ritonavir, a drug already marketed for HIV/AIDS).
- ▶ Increased the scale of drug testing in our mouse model of ALS, evaluating 28 drugs and discovering 3 new "hits", establishing our program as the recognized global leader in the application of this model to drug discovery.
- ▶ Established 4 targeted external research collaborations with key academic laboratories and partnered with more than 25 for-profit pharmaceutical and biotechnology companies to reinforce and extend our ALS knowledge base, revealing new opportunities for identification of possible new treatments.
- ▶ Added key pharma- and biotech-experienced scientific leaders to our R&D staff, including Dr. Chris Pazoles (Chief Operating Officer and Head of R&D) and Dr. Phil Lambert (Director of Pharmacology).
- ▶ *see page 3 for more...*

Patient Services Highlights 2002

- ▶ Held four ALS 101 seminars to provide patients, caretakers, and physicians with information on new research and treatments for ALS.
- ▶ Responded directly to more than 3,000 inquiries from ALS patients, families, and friends. Wrote, printed, and distributed three research newsletters to a circulation of more than 10,000 patients, families, physicians and researchers.
- ▶ Investigated controversial, experimental therapies for ALS, providing objective answers to patients' questions on these untried therapeutics and their proponents.
- ▶ *see page 9 for more...*

Advancement Highlights 2002

- ▶ Raised more than \$4.3 million for ALS research, a 7% increase over 2001.
- ▶ Doubled revenue of the Family and Friends Community (FFC) to \$1.8 million.
- ▶ Enabled 68 FFC fundraising initiatives on behalf of ALSTDF to raise money in support of ALSTDF's drug discovery program.
- ▶ Successfully obtained grant funding to sponsor the first clinical trial arising from ALSTDF's screening program.
- ▶ Provided grants to outside researchers as well as funding the ALSTDF laboratory.
- ▶ *see page 7 for more...*

ALSTDF – The ALS Therapy Development Foundation

A nonprofit biotechnology company dedicated to developing effective treatments for today's ALS patients. ALSTDF combines the passion and dedication of a nonprofit organization with the entrepreneurial and scientific spirit of a biotechnology company. ALSTDF runs the leading drug discovery program focused on ALS and combines in-house technology and expertise with key scientific collaborations to accelerate the process of finding effective treatments for ALS.



Accelerating Drug Discovery For ALS

During 2002, ALSTDF's Research & Development team made many significant strides forward in its quest for an ALS treatment and cure. Several expansions of existing systems and programs allowed us to pursue a greater number of targets in ALS, and to test more drugs aimed at those targets. In addition, key staff additions and the appointment of a Clinical Advisory Board has increased ALSTDF's effectiveness, visibility, and recognition as leaders in drug discovery for ALS.

Exploring Multiple and New Targets for ALS

Data from both internal and external research efforts continue to lead ALSTDF towards pursuit of a broad range of promising drug targets across important ALS disease pathways. These pathways include inflammation, apoptosis, protein misfolding, excitotoxicity, cell replacement, and more recently, proteasome dysfunction and cell cycle regulation. Cell cycle targets are of particular interest since they may represent more "upstream" disease pathways leading to the activation of "downstream" pathways such as changes in basal cell metabolism, inflammatory/immune activation, glial proliferation, and apoptosis. This novel class of targets has yielded new drug leads, some of which have potential for clinical development.

ALSTDF Clinical Advisory Board

Benjamin Rix Brooks, M.D.
Director of the ALS Clinic and the MDA/ALS Clinical Research Center at the University of Wisconsin-Madison

Robert H. Brown, Jr., M.D., D.Phil.
Director of the Day Neuromuscular Laboratory and Muscular Dystrophy Clinic at the Massachusetts General Hospital

Merit Cudkovicz, M.D., M.Sc.
Co-Director of the Neurology Clinical Trial Unit and ALS Center at the Massachusetts General Hospital

Dallas A. Forshev, R.N., B.S.N.
Manager of the ALS Center at the University of California San Francisco

Robert Miller, M.D.
Director of the Forbes Norris MDA/ALS Clinical Research Center at California Pacific Medical Center

Hiroshi Mitsumoto, M.D.
Medical Director of The Eleanor and Lou Gehrig MDA/ALS Research Center at Columbia University

Richard K. Olney, M.D.
Director of the ALS Research and Patient Care Center at the University of California San Francisco

Jeffrey Rothstein, M.D., Ph.D.
Professor of the Robert Packard Center for ALS Research, and Director of the MDA/ALS Clinic at Johns Hopkins University

Pictured Above: ALSTDF uses clinical chemistry to evaluate drugs.

Electronic Research Pipeline System

ALSTDF established a comprehensive data mining and information management process to evaluate its growing pool of drug targets (currently 50) and lead compounds (more than 400 in our pipeline). Of these lead compounds, 28 were selected for *in vivo* drug screening in our facility in 2002, and a total of more than 60 screening studies were completed.

External Research Program

Our External Research program was established to better inform our understanding of the ALS disease process and to help us select new and better targets for drug intervention. This outreach program initiated nearly 30 collaborations in 2002 with both academic and industry researchers inside and outside of the ALS field to acquire compounds for drug screening and to initiate targeted experiments that fill key gaps in the body of ALS knowledge.

Clinical Advisory Board

In 2002, ALSTDF appointed a Clinical Advisory Board comprised of leading researchers in ALS. The establishment of a Clinical Advisory Board was a critical step in ALSTDF achieving its mission to develop effective treatments for people living with ALS. Experts in researching, diagnosing and treating ALS, the group will partner with ALSTDF to provide scientific and strategic input on advancing ALSTDF's drug development program.

"Over 2002, we strengthened and further professionalized ALSTDF's research and development program. We are better positioned than ever to deliver against our time-critical mission."

CHRISTOPHER PAZOLES, Ph.D.

CHRISTOPHER PAZOLES, Ph.D. Chief Operating Officer, Head of R&D

Chris joined ALSTDF in 2002, bringing 21 years of experience in the pharmaceutical and biotechnology industries to ALSTDF. He most recently was Vice President of Research for Phytera, Inc., a drug discovery and development biotech company, where he built and led a multidisciplinary and multi-national research team and helped forge a variety of corporate alliances and partnerships. Before Phytera, Chris held a series of positions in Pfizer's Central Research Division, including management roles in the areas of neuroscience and inflammation discovery. At Pfizer, he was also involved in numerous pre-clinical and clinical development programs, ultimately serving as Director, Exploratory Development Planning before leaving Pfizer to join the biotech industry. Chris holds a Ph.D. from the University of Notre Dame in microbiology and biochemistry and spent five years as a post-doc at the National Institutes of Health in Bethesda, MD.

Chris led the R&D team through a number of improvements and refinements to the research pipeline and drug discovery processes that enabled ALSTDF to: more effectively manage the 400-plus drug leads considered for testing in the lab; secure a newly appointed Clinical Advisory Board; and move a drug candidate toward clinical trial.





Discovering Effective Treatments for People Living with ALS

IN OUR LAB

ALSTDF runs the largest drug screening program in a mouse model of ALS. In 2002, the number of mice housed and compounds screened in the SOD1 mouse model increased with the availability of more space in our new facility. Six drug screening studies were initiated each month, each involving 40 to 50 mice. As a result, there were approximately 1,000 mice in our facility and more than 20 drug studies ongoing at any one time.

State-of-the-Art Laboratory Facilities & New Staff

In 2002, ALSTDF relocated and expanded its drug-screening program, the ALS Hope Drug Discovery Center, to a state-of-the-art laboratory and animal space located in the Partners Healthcare Building in Cambridge, MA. The new space enabled us to house more than 1,000 mice in an SPF animal facility run by Harvard. Harvard provided all facilities management and animal care support, as well as use of the procedure rooms in the facility suitable for all surgical procedures.

In addition to the animal facility, we have dedicated laboratory space that holds all of our equipment for drug formulation, pharmacokinetic analysis, hematology, clinical chemistry, necropsy, histochemistry, and molecular biology. This year, ALSTDF has expanded the scientific expertise of their research team by adding two scientific leaders from the biotechnology industry. Our laboratory team now consists of a Director of Pharmacology, Laboratory Manager, eight Research Technicians and a Formulation Scientist. This team has all the

necessary experience and expertise to effectively carry out drug evaluation studies in the SOD1 mouse model.

Our First Clinical Drug Candidate

In 2002, the first drug from ALSTDF's screening program to be advanced towards clinical study in ALS patients was identified – ritonavir (a protease inhibitor currently marketed to treat HIV/AIDS). Additionally, a grant was secured to cover the majority of the cost of this study.

Ritonavir was chosen for study in our mouse model of ALS because its reported pharmacological actions overlap with several ALS disease pathway targets. In this model, ritonavir produced modest but statistically significant slowing of disease symptom progression and extended lifespan. It has the potential to produce larger effects in humans. It also displayed serious side effects in the mice, requiring researchers to work out a delicate balance of toxicity and efficacy before deciding to advance ritonavir towards the clinic. Its side effects in humans are well-characterized and can also be quite serious. For this reason, the initial clinical trial of ritonavir in ALS patients (scheduled to start in late 2003) will focus on evaluating its safety profile, with sufficient disease assessments to detect any trends towards efficacy.

PATIENTS TODAY

Treatment Information Reports

ALSTDF maintains its commitment to patients by acting as a source of coherent information that empowers patients to partner with their physicians regarding their treatment. In 2002, our first full-time staff Treatment Coordinator answered more than 2,000 individual requests for information. Significant updates and improvements to www.als.net added in-depth information on drugs under evaluation, screening studies, and the status of certain lead compounds.

“These refinements to screening should ensure that every drug is tested at a safe dose, and that each study is designed to generate the most reliable and accurate results.”

PHIL LAMBERT, Ph.D.

PHIL LAMBERT, Ph.D. Director of Pharmacology

Phil is a neuroscientist with 14 years of experience in research and drug discovery. He has worked on novel approaches to treating diseases of the neural and endocrine systems at both large pharmaceutical companies and in the biotech industry. Before joining ALSTDF, he was Director of Pharmacology for Waratah Pharmaceuticals, a start-up biotech company developing an islet regeneration therapy to treat type I diabetes. Phil led a group responsible for both the in-house and external drug development studies, which successfully drove the therapy into clinical trials. Before Waratah Phil held several positions in the Neural and Endocrine Biology Group at Regeneron Pharmaceuticals. Phil holds a Ph.D. in pharmacology from the University of London, England and spent 4 years in academia at Emory University Medical School in Atlanta, GA.

Under Phil's guidance, ALSTDF's laboratory made a number of improvements to the screening process that will allow more cost-effective testing of potential treatments. These changes included a full-scale statistical analysis of the mouse colony used in the screening and a program called "pilot screening" – brief, 7-day studies pre-testing the selected dose of each drug to identify potential toxicity problems.



ALS 101

ALSTDF brought together hundreds of patients, family members, and friends during 2002 into an open atmosphere to share information with one another about research and treatments for ALS. Patients travel from across the country – and, sometimes, across the world – to attend this free seminar on ALS.

The goal of ALS 101 is to assist patients and their families in most effectively working with their physicians and with all other resources available to them in charting a course of treatment for their disease.

In 2003, ALSTDF plans to take ALS 101 on the road to cities across the country, so that ALS patients who are less able to travel will still have access to this seminar program.

Pictured Above: ALS patient Jon Russell speaks with ALSTDF's Patient Services Specialist Mary Beth Parks at ALS 101.

Advancement

In its short four-year history, ALSTDF has raised over \$13 million through the generosity of individuals, the Friends and Family Community, foundations, corporations, and special events. In 2002, gifts totaling more than \$4.3 million were received from over 6,655 sources, representing an increase of seven percent in overall giving from 2001. In addition to this achievement, ALSTDF is proud to report it spends 85 cents of every dollar raised directly on research and patients. It is the generosity and thoughtfulness of our philanthropically-minded donors that have made these accomplishments a reality. Thank you from all of us at ALSTDF for your dedicated financial support. We hope you will continue to contribute to our research and mission as we augment our efforts to more efficiently and effectively identify, select, screen, and discover therapies for ALS.

Corporations

Pharmaceutical and biotechnology companies are a vital part of ALSTDF's growing scientific research program. Aligning the resources of these companies with our own is essential in order to fully achieve our mission in several ways, including:

- Accessing targeted drugs for testing in our mouse model of ALS. To date, we have successfully obtained donations of costly (or even impossible to purchase) drugs from more than 25 companies. In total, the market value of these drugs is nearly \$2 million.
- Forging sponsored research partnerships to test company's promising drugs and/or to improve our drug testing technologies. Such partnerships represent a new revenue source for the Foundation.

Foundations

In 2002, ALSTDF raised nearly \$1 million thanks to the generosity of several foundations (see p.12). A number of these gifts, including those from the California-based Larry L. Hillblom Foundation and the St. Louis-based Jack Orchard ALS Foundation, focused directly on specific research projects, while others, including another significant grant from an anonymous foundation as well as gifts from ALS Hope – the Chris Hobler/ Jean Maritz ALS Foundation, provided much-needed financial support at a crucial time. We aim to cast our net even wider in the coming year, seeking support from foundations nationwide and increasing the number of grants in 2003.



ALEX & BRIT D'ARBELOFF Founding Contributors to ALSTDF

Two of ALSTDF's most faithful supporters since its early days of operation are Alex and Brit d'Arbeloff. Shortly after ALSTDF was founded, the d'Arbeloffs launched ALSTDF into action with their first gift of \$100,000. The next year, they followed up with a \$300,000 gift, and in the summer of 2002 their support increased exponentially with a generous, thoughtful donation of \$1 million.

The d'Arbeloffs are a successful Boston-area couple, active in the business and philanthropic communities. Alex is the cofounder of Teradyne, Inc., a leading manufacturer of automatic test equipment and interconnection systems for the electronics and telecommunications industries; he retired as chairman of the firm in May 2000, when he increased his involvement at MIT. He graduated from MIT in 1949, recently retired as chairman of the MIT Corporation, and serves on several area boards. Brit received her masters from MIT in 1961, is also an active member of the MIT community and serves on several committees.

Thanks to the d'Arbeloff's significant contribution, ALSTDF has grown into the organization we are today, substantially increasing the capacity of our drug discovery program.

“There are an awful lot of groups to support in the health industry,” says Brit. “But when you see something like this that is obviously different, it’s exciting.”

BRIT D'ARBELOFF

Donors

Leadership Circles

As a member of one of the Leadership Circles, you demonstrate your leadership through annual gifts of \$1,000 or greater. You provide support for ALSTDF's laboratory operations, patient services, and clinical research into potential treatments for ALS. Thank you to all members of our Leadership Circles who continue to enable ALSTDF to make significant strides toward slowing, arresting, and curing ALS.

Founders' Circle

\$100,000-plus annually or \$1 million or more cumulative giving

- ALS Hope
- Anonymous
- Jean Angell Fund
- Alex and Brit d'Arbeloff
- Fran Delaney Fund
- The Beatrice P. Delany Charitable Trust
- DeeDee Fornengo Fund
- The Larry L. Hillblom Foundation
- George & Daphne Hatsopoulos
- Mary Lou Krauseneck Fund
- Stephen Milne Society
- Joy Milne
- The Jack Orchard ALS Foundation
- Edward Scott

Governors' Circle

\$25,000-plus annually

- Jim & Susan Airey ALS Fund
- Connecticut Friends For ALS Research
- Erie Indemnity Company
- Jennifer Huntington
- Tom Larsen
- William and Betsy Leitch
- Anthony Tucker

Directors' Circle

\$10,000-plus annually

- Adelard A. and Valeda Lea Roy Foundation
- ALS Family Charitable Foundation, Inc
- Gebzan & Suzanne Anton Bear, Stearns & Co., Inc.
- Ralph Borneman Jr. Boston Bruins
- Jim & Endina Canty
- Dick Douglass Effort
- Compaq Computer Corporation
- David Green Effort
- Marlene Hess
- Will Hubben ALS Research
- Jewish Communal Fund
- Nancy & Jeffrey Halis Philanthropic Fund

- Gail Kendall
- Larry Linden
- Betty Luke
- Elliot Macht
- Mark Mance
- Match Computer
- Pharmacyclics, Inc.
- Pioneer-Standard Electronics, Inc.
- Jim Raspanti Fund
- Mark Reed III
- Ride For Life
- David Searls
- John & Iola Sobeck
- St. Hubert's Knights of Columbus
- State of New Jersey Division of Administration
- The Thorson Foundation
- Total Tec Systems, Inc.
- Jeff Ureel Fund

Associates' Circle

\$5,000-plus annually

- Abrams Capital
- Bryan & Mark Allain Fund
- Allain-Lebreton Co. LLC
- Boyer & Pentek, Inc.
- Regina Dow
- Doug Duren Effort
- Fife Family Foundation Inc.
- Bill Fraser Effort

- Friends of Harry Gianneschi
- GlaxoSmithKline Foundation
- George & Mary Grey
- Tim Hines
- Jack Hoffman
- Richard & Ilene Jacobs
- Walt & Kathy Knopp
- Bradley Kress
- L & M Cleaning Services, Inc.
- Don & Michelle LaBelle
- MacDonald Illig Jones & Britton LLP
- Margolis Edelstein
- Malcolm & Andy Marshall
- McCloskey & Fritsch, P.C.
- Roger & Courtney McEniry
- Mistick, Inc.
- Serena Moon
- Andrew Nodaros Fund
- Paymentech
- Robb, Leonard & Mulvihill
- Rothman Family Foundation
- SAFELITE Glass Corp.
- The Skoll Community Fund
- Marty Stayer ALS Research
- John & Joan Ureel
- Norm & Molly Wagner
- Waste Management, Inc.
- Matt White
- Zimmer Kunz PLLC

Donors Continued on p. 11

ALSTDF through the eyes of Amy Whipple and The Mary Lou Krauseneck Fund

In June of 2000, my aunt Mary Lou was given the diagnosis of ALS. Her prognosis offered her no hope and she was told nothing could be done.

Shortly thereafter we discovered ALSTDF and its commitment to patients living with ALS today.

We recognized increased funding would enable them to get equipment they needed, to hire top researchers and scientists, and to purchase SOD1 mice for drug studies.



Pictured: Bernadette Cooper, Amy Whipple, and ALSTDF's Maureen Oakes.

Our family then had virtually no fundraising experience. Our first project was a cookbook put together by close family and friends. A few years later we have been joined by a dedicated, passionate group of men and women that make our fundraising efforts possible. Over this past year, we were blessed to see our ranks swell to more than 100 volunteers. We have raised nearly \$500,000 for ALSTDF over the last three years with their help.

Mary Lou is living her life with an incredible amount of hope, passion, strength, courage, and happiness. She gains this strength knowing that ALSTDF is working to find a cure. We have hope because of ALSTDF.

- AMY WHIPPLE
STERLING HEIGHTS, MI

In 2002, ALSTDF's Family and Friends Community

(FFC) doubled their income from 2001, bringing in a total of \$1.8 million. This was made possible through several additions to the FFC program, including an increase from one to three full-time support staff with fundraising and event-planning experience.

FFC also provided families with new and expanded resources to assist them in their fundraising endeavors, including a Family and Friends Community Tool Kit that helped new members understand

what was involved and get their efforts started. In addition, the new FFC website was created as

a place for community partners to create their own web page to tell their personal story and to create a fundraising and awareness tool to send to their network of family and friends.

visit: www.alscommunity.org



Family & Friends Community Partners

The Family and Friends Community is a key piece of ALSTDF's fight to develop treatments and a cure for ALS.

This fast-growing group of family and friends has increased our motivation and strength to find a cure for ALS and together raised approximately \$1.8 million in 2002. Thank you to each and every person that made the following efforts possible, and exhibited ALSTDF's values of Courage and Love.


- ALS Family Charitable Foundation, Inc.
- Alan Inglis
- Andrew Nodaras Fund
- Anna Brown Effort
- Anthony Tucker
- Bernard Salmand Effort
- Bill Fraser Effort
- Bryan & Mark Allain Fund
- Carol Lee Cordes Memorial

- David Green Effort
- Dean Adraktas Fund
- DeeDee Fornengo Fund
- Dick Douglass Effort
- Doug Duren Effort
- Dunphy Sisters Fund
- Elliot Macht
- Fran Delaney Fund
- Friends of ALSTDF


- Friends of Harry Gianneschi
- Friends of Janet Sharp
- Friends of My Heart
- Jack Hoffman
- Jack Orchard ALS Foundation
- Jean Angell Fund
- Jeff Ureel Fund
- Jim Fitzhenry Fund
- Jim Raspanti Fund
- Jim & Susan Airey ALS Fund
- Joli Day Spa
- Judy Harrison Effort
- Kathy Rivers Fund
- Larry Manes
- Lauretta Stott Fund
- Liz Hax Fund
- Maes Family Fund
- Malagodi Memorial Fund
- Marie Garratt Memorial Fund
- Marty Stayer ALS Research
- Mary Lou Krauseneck Fund
- Matt Dowd Fund
- Michael Donnelly Falcon's Cry Fund
- Paley/Harold Fund
- Paul Gerbick Fund
- Peggy Lanza Fund
- Randee Brown Fund
- Richard M. Mott Effort
- Stephen Heywood
- Stephen Milne Society
- Steve Carlin
- Steve Fowler Fund
- Steve Heppler Fund
- Steve Lewis Fund
- Tom Larsen Challenge
- Trude Klugman
- Will Hubben ALS Research
- William Bence Effort
- Wolfmom Family Fund

FINANCIAL REPORT 2002

	2002	2001	2000
Assets			
Cash	1,265,312.00	890,304.00	217,482.00
Investments	574,260.00	974,999.00	469,264.00
Fixed Assets, Net	151,340.00	117,763.00	56,057.00
Other Assets, Net	40,287.00	18,912.00	13,680.00
Total Assets	2,031,199.00	2,001,978.00	756,483.00
Liabilities & Net Assets			
Liabilities	435,021.00	25,126.00	14,803.00
Net Assets	1,596,178.00	1,776,852.00	741,680.00
Total Liabilities & Net Assets	2,031,199.00	2,001,978.00	756,483.00
Support & Revenue			
Contributions	2,240,704.00	2,863,153.00	1,433,055.00
Grant Receipts	641,185.00	1,000,000.00	-
Fundraising Events	1,524,614.00	58,116.00	93,915.00
In-kind Donations	19,072.00	21,828.00	30,650.00
Interest, Dividends & Gains Realized and Unrealized	(90,158.00)	74,972.00	4,506.00
Total Income	4,335,417.00	4,018,069.00	1,562,126.00
Expenses			
Research & Development	3,600,967.00	2,204,794.00	732,050.00
Patient Services	218,503.00	71,639.00	86,244.00
Fundraising	451,439.00	333,795.00	95,195.00
Management & General	245,183.00	372,667.00	130,136.00
Total Expenses	4,516,092.00	2,982,895.00	1,043,625.00
Increase in Net Assets	(180,674.00)	1,035,172.00	518,501.00
Net Assets: Beginning of Year	1,776,852.00	741,680.00	223,179.00
Net Assets: End of Year	1,596,178.00	1,776,852.00	741,680.00



WHERE THE MONEY GOES



WHERE THE MONEY COMES FROM

2003 Goals

- ▶ Commence clinical study of ritonavir in ALS patients; advance another potential new treatment towards the clinic.
- ▶ Acquire technologies and expertise to further increase the pace and value of our drug testing program, including identifying biomarkers of disease progression that can dramatically accelerate drug studies in animals and in patients.
- ▶ Harvest the wide arena of ALS-related research information stemming from our external research partnerships, steering our drug testing efforts into more fruitful areas.
- ▶ Continue openly sharing our key research findings with the broader scientific community and establish a Scientific Advisory Board to help optimize our research strategies and tactics.

ALSTDF Board of Directors

- ⌘ Dennis A. Ausiello, M.D.
- ⌘ John Heywood, Ph.D.
- ⌘ Jenny Huntington
- ⌘ Fran Delaney
- ⌘ Timothy Hines
- ⌘ Spiros Jamas, Sc.D.
- ⌘ Steve Fowler
- ⌘ George Hughes
- ⌘ David Searls, Ph.D.

Benefactors' Circle
\$1,000 - plus annually

Richard & Iris Abrons
A/C Associates of N.Y., Inc.
Thaddeus Plis
ALS Benefit Account
Christopher & Dawne Altemus
Amherst, LLC
Robert Amrhein
Anonymous
John & Diana Appleton
Arie and Ida Crown Memorial
Milton Arnold
Art-O-Craft
Michael & Jean Artin
Scott Asen
AT&T Foundation
Atlantic Mutual Companies
Back To Basics Plus
Gerald H. Baker
Richard Baldwin
Barr Foundation
Victor & Linda Battani
Thomas Beigel
Ray Bell
William Bence Effort
Berlinc Insurance Agency, Inc.
Bernard Salmand Effort
Ted & Peg Bernhardt
Bittel & Co.
Marc Blais
John & Colleen Bloomstine
Body-Borneman Associates Inc.
Matthew Bovenzi
Paul Boylan
Ronald Boyles Sr.
James M. Bradford
D.J. Brady
Robert Brest
John J. & Elaine Brinling Jr.

Marvin Brittman
Daniel & Estrellita Brodsky
Harold & Phyllis Brourman
Meg Brown
Rande Brown Fund
Buchanan Ingersoll
Buckeye Coffee House
Kennett & Barbara Burnes
Buzz & Helen Burrage
Robert & Alice Butler
John E. Callahan Jr.
Michael Calvey
Robert F. Carr III
Carr Insurance Agency Inc.
Richard & Paula Casey
Castek Software Factory Inc.
Celik Insurance Agency, Inc.
Rich & Lisa Ceuninck
Bob & Laurie Champion
Channel Bio Corp.
Bill Childers
John Chirichiello
CITGO Petroleum Corporation
Citizens Financial Group
Alf & Jenny Clark
Client Business Services, Inc.
Coin Depo Corporation
Louis F. Colaizzo
Tom & Nancy Colatosti
Peter & Kathy Collias
Katherine Collins
Dave & Lucy Concordia
Stephen & Bernadette Cooper
Robert H. Cox
CP&S Mark Sullivan
Steve & Pat Crandall
Dominic & Pamela Cruz
D'Alesio-Trettel Insurance
Services, Inc.
Daniel Boone Coffee House
Richard & Peggy Danzinger
Davic Inc.
David & Lauren Gorter

Davies & Davies Insurance, Inc.
Davis-Vandenbossche Agency, Inc.
Scott Day
Jonathan & Emme Deland
Fran & Jan Delaney
Steven Denning
Desert Schools
Diamond Cluster International, Inc.
Richard & Terri DiBella
Disabled American Veterans,
Chapter 27
Michael Donnelly Falcon's Cry Fund
Greg and Julie Dowd
Matt Dowd Fund
Robert & Betty Dreyer
DSA Convention Services, Inc.
Edgewood Management Company
Gary & Joan Eichhorn
Enterprise Rent-A-Car of Pittsburgh
Erie Community Foundation
Erie Indemnity Company
Executive Jet International, Inc.
Joann Thibault
Ziggy & Suzanne Ezekiel
B. Fedorov UFG428
Douglas Fitzgerald
Jay & Susan Forrester
Steve Fowler Fund
Howard Frank
Kathleen Freed
Wendy Frey Caswell
G.L. Herndon Insurance Agency, Inc.
Philip Garcia
GEICO Philanthropic Foundation
General Casualty
Paul Gerbick Fund
Dino & Barbara Giamatti
Brian & Veronica Glynn
Lou & Celia Gody
Goldman, Sachs & Co.
Rodney L. Goldstein
Jim & Susan Goodfellow
Gorter Family Foundation

Harry & Leila Gould
Granite State Plumbing &
Heating, Inc.
Steven Grates
Jean Green Oehler
Julie Greiner
Roger & Sherryl Griffin
Angelo & Sharon Guadagno
Richard & Janet Gullborg
Gullborg Insurance, Inc.
Silver Mountain Foundation for
the Arts
Frank Hable
Frank Hale III
Robert B. Hallman
Linda Harder
Harleysville Insurance
David Harmon
George Harrington
Charlie & Stephanie Harrold
Eric & Janet Hartz
Liz Hax Fund
Michael Hellman
John & Maire-Laure Helmkampf
Marv & Janet Henzlik
Edie Heppler
Steve Heppler Fund
Gretchen Hicks
Hireminds LLC
Frank William Hirt
Virginia Hoffman
Ralph & Amy Hollis
Hooper Holmes, Inc.
James & Susan Horvat
Larry Huntington
Hybrid Parking Solutions, Inc.
Insurance Consultants of Pittsburgh
Insurance Consultants of
Rochester, Inc.
Insurance Information Institute, Inc.
Insurance Professionals of NW PA
J & N Kalishman Family Foundation
J.P. Morgan Chase Foundation

Spiros Jamas, Sc.D.
John R. Lyman Company
Jordan Industries, Inc.
Bill Jorgensen
Brian & Julie Simmons
Leo & Emily Kahn
Kalchthaler Insurance Agency
Kevin & Susan Keefe
Chris & Anne Keller
John A. Kelley Jr.
M. S. Kelly UFG428
Ken Hershberger Insurance Agency
D. Khilov
Kim Kraft, Inc.
Jeffrey Klein
Klein Insurance
Kloudgenet
Lou Kobbs
Mary Kobbs
Ben & Mary Koehler
Mary Lou Krauseneck
Jeffrey LaGueux
LandAmerica-Lawyers Title
Dan & Sharry Langdale
Geoffrey & Eileen Lanza
Peggy Lanza Fund
Robert & Kimberly Lanza
Jim & Diana LaPointe
Lawrence R. Dowling
Insurance Agency
Fred Lawrence
Bob & Mary Leisure
David Leyrer
Steve Lewis Fund
Krista Lincoln
Ralph Lipizzi
Hank & Lori Lorant
Scott & Marian Lord
Phillip Love
George Lucore
Jeffrey A. Ludrof
B. Lane MacDonald
Bill & Diane MacDonald

David MacDonald
William MacDonald
Mad River Foundation
Maes Family Fund
Robert & Kathy Mahoney
Jim Malanson
Ed & Maxine Manes
Subash Mani
John Martin
Michael Matfess
Matrix One
McCarthy Wilson
John McDonald Constructive
Consulting
Thomas McKie
Thomas McNally
Meet With Success, Inc.
Eduardo Mestre
Bora & Ljubica Mikic
Chester A. Miller Jr.
Milliren Insurance Agency
Jim & Judy Milton
Steve & Cindy Mitchell
Thomas Morgan
Roland & Karen Morris Jr.
Victoria Morville
Dennis & Faye Mosco
Richard M. Mott Effort
MSRC Co.
John & Catherine Nathan
National Association of
Independent Insurers
Hank & Kim Nichols
North Carolina Farm Bureau
Dave & Marcia Noto
Raymond & Carole Noveck

Jack Novia
Nutter, McClennan and Fish
Martin & Mary O'Connor
Michael & Holly O'Connor
Philip & Jennifer Ogden
OnProcess Technology, Inc.
Open Society Institute
Mark Ostaseski
Paley/Harold Fund
Mike & Joyce Paquette
Richard & Laura Parsons
Peerless Insurance Company
Peninsula Community Foundation
Dean & Diane Petitpren
Phillips-Wisniewski Insurance
Agency
PNC Bank
Tony Prince
Thomas Reardon
John & Margaret Roll
Robert & Olivia Rutkowski
C. Ryan UFG428
Nancy Sachar
Sales Research Institute, Inc.
Bernard & Jacqueline Salmand
A.J. & Pamela San Clemente
M. James Sandlings
Antonio & Mary Sandoval
Cynthia Sauln
Scott Scherrer
Stephen R. Scholl
Bob & Cynthia Schuneman
Scott Nathan
Kara Seymour
Joe Shambo Jr.
Ascher & Katherine Shapiro
Regan & Kathy Shea
Robert & Mary Sheh
I. Sherbovich UFG428
S. Shmeley UFG428
Jim & Stacey Shortt
J. Scott Sinclair
Jeff & Janet Smith
John P. Sommerwerck
Valerie Sontrop
Spencer Insurance Agency, Inc.
Richard & Janet Sprague
St. Marys Insurance Agency, Inc.
Stainbrook Insurance Agency
Stanberry Insurance Agency, Inc.
Lou & Judi Stanford
Barry & Cynthia Stiles
Lauretta Stott Fund
Rollin & Roxanne Swanson
Ted Parker Insurance Agency
The Collis/Warner Foundation
The Computer Merchant, Ltd.
Donald Rice
The Genzyme Community
Foundation
The Insurance Federation of PA, Inc.
Kenneth Hanly
The Larry N. George Agency
Atsuko K. Fish
The McArdle Agency, Inc.
The Millipore Foundation
The Ron Bagarella Memorial
Foundation
The USAA Foundation
Jeffrey & Evelyne Thomas

Michael Thomas
W. Rodney Thomas
Donald Thomson
Bob Tschanz
Phyllis Tschanz
Walt & Linda Tucker
UBS/PaineWebber Contributions
Committee
United Way of New York City
United Way of North Central
Mass., Inc.
United Way of the Capital Area
United Way of The National
Capital Area
Jan & Linda Van Gorder
Gerard Ventura
Robert & Patricia Volland
W.L. Davison Forensic Services, Inc.
Wal-Mart Foundation
Walker MacCartney Insurance
Services
Wallin Insurance Agency, Inc.
The Shoreland Foundation
Frank & Lois Wankerl
Ed Webster
Terry & Susan Welch
Ira & Phyllis Wender
Kristopher & Cheri Wesinger
Westborn Chrysler Jeep, Inc.
Amy White
Wallace Wielock
Wiester Insurance Agency
Peter & Nancy Wilderotter
William G. Mechling Insurance
Agency, Inc.
Christopher Williams
Robert & Denise Williams
David & Ellen Wilson
Martha Berkman Winfield
Wolfmrom Family Fund
Brian Wruble
Yoder-Hershberger Insurance
Peter & Dana Zaphiris
Michael S. Zavasky
Jide Zeitlin
Douglas F. Ziegler

Friends
\$500-plus annually

ALSA Rhode Island
Accenture Team at the ERIE
Bernard Adams & Edna Travis
Dean Adraktas Fund
Stephanie Adraktas
Noubar Afeyan
Nile Albright
The Alexa P. Good ALS Foundation
Algonquin Gas Transmission
Company
Amica Companies Foundation
Anderson Logging & Lumber
Roger & Carol Angell
Anheuser-Busch, Inc.
Anonymous
Robert Antonelli
Assure America Corp.
Kurt & Jayne Atchinson
Aurora, Inc.
Axeda

Robert Bachman Alexis & Samantha
Bachman Fund
James & Margaret Baldrige
Margaret Baldrige
Bruce & Lissa Barron
Ed Barry
Thomas & Cheryl Beaudoin
Mike & Lisa Beauvais
Kathleen & Paul Benick
Bernard Michals Insurance Agency
Donald & Trina Best Jr.
Black Diamond Properties, Inc.
Janet L. Blakeman
Peter Bloom
David & Roberta Bolton
Kenyon Bolton
Robert Bonazoli
Richard & Cathy Boskey
Brian Brady
Thomas & Mary Ellen Brearley
Hugh Bridgford
Tom Britton & Debra MacLaughlin
Carolyn Brock
Alan & Ashley Brodine
Anna Brown Effort
Browning Insurance Agency
Brunner Insurance
Hung Bui
Nat & Rosemari Buono
Rick & Ellen Bush
Richard Button
C. F. O'Connell & Sons, Inc.
Michael & Lisa Callaghan
Joe Caloggero
Sheila Calvert
Abigail A. Canfield
Bob Carden & Michelle Mortier
John & Ruth Carey
Carney Family Foundation
Patrick & Nancy Carroll
Steve Carter
Wendy Caswell
Centimark Corporation
Sumir Chadha
John & Linda Chayka
Allen & Jane Cheever
Chesapeake Coffee House
Sam & Vickie Childers
Carmine Chirichiello Jr.
David & Sandy Christensen
Chubb Insurance Group
CNA Foundation
Bob & Kathleen Cohen
Combined Federal Campaign
Commercial Contracting
Corporation
Commodore Perry Coffee House
CompuCom
Eugene & Anne Connell
Construction & General Laborers'
Union Local 22
Costello Plumbing Co., Inc.
Cozen O'Connor Attorneys
Richard & Christine Critchfield
Crossways Charitable Foundation
Henry Crouse
Edgar Cullman Jr.
Ruth H. Cunniff
Randy & Diane Currier
Barry D'Andrea

Donors Continued on p. 14

Matching Gifts

ALSTDF is grateful to the many employers who generously match the gifts we receive from their employees. The following list recognizes those companies who made matching gifts in the past fiscal year, which ended on December 31, 2002.

ADC Foundation
Altman Foundation
American Express Foundation
Bank of America Matching
Gifts Program
CITGO Petroleum Corporation
Compaq Matching Gifts Program
Deutsche Bank Americas
Foundation
Dominion Resources
Fiduciary Trust
Fleet Matching Gift Program
Freddie Mac Foundation
Matching Gifts
Freedman Financial

Gartner Group Charity Fund
General Atlantic Service Corp. MG
George P. Johnson Company
Giddings & Lewis Foundation, Inc.
GlaxoSmithKline Foundation
Goodrich Foundation
Gordon & Betty Moore
Foundation MG
Hewlett Packard
J.P. Morgan Chase Foundation
John Hancock Financial
Services, Inc.
Johnson & Johnson
Kemper
Liz Claiborne Foundation

Merrill Lynch & Co. Foundation, Inc
MFS Investment Management
Open Society Institute
Oracle Corporation Matching Gifts
Pfizer Foundation Matching
Gift Program
Pioneer Investments
Matching Gifts
Pitney Bowes Matching
Gift Program
Polaroid Fund
Prudential Foundation
Matching Gifts
Reuters America
Rockefeller Financial Services, Inc.

Scudder Kemper Investments, Inc.
The Chase Manhattan Foundation
The Millipore Foundation
The Prudential Foundation
Matching Gifts Program
Tisch Foundation, Inc.
TurboCare, Inc.
Tyco International (US) Inc.
Washington Mutual Foundation
Wellington Management
Company, LLP

Memorials

ALSTDF acknowledges the following individuals who received gifts made in their memory during 2002. Our staff extends our deepest sympathies to their families and friends who continued to fight ALS even after their loved ones' death.

Edward Abramson	Helen Craig	Donna Goudreau	Elaine Maples	Sylvia Settlow Silver
John Algeo	Larry Davis	Louis Govoni	Evelyn Marran	Robert Singer
Henrietta Reid Allain	Nancy Hirschmann Dean	David Green	Anne McDonnell	Shirley W. Smith
Bryan Allain	Linda Sue DeBiase	Doris Hable	John McGrade	Patricia F. Smith
Dirk Angelman	John Leigh Decker	Jill Haines	Margaret McLaughlin	Patricia Smith
Theresa Barori	Bill Dehn	Mordecai Halpern, MD	Rita McMahan	Barbara Snyder
Steve Beason	Sean Paul D'Entremont	Ikram Haque	Tom McMillan	Beula Sonders
John T. Beaty	Bryan DiMaria	Todd Harris	Joan McNeil	Cynthia Spier
William Bence	Lindsay Disharoon	Erwin Hefka	Donald McTarnaghan	Harvey Stahl
James Benjamin	Ben Disharoon	Maxine Heppler	Faranak Fatami Moir	Marty Stayer
Andrew Berezin, M.D.	Leonard Dorfman	Douglas Hicks	Laurie Moore	Rick Stemrich
Al Berman	Tim Doughty	Terry Hiemstra	Stanley Moss	William Stevenson
Robert Blanchard	Joyce Doyle	James Homan	Richard Mott	Harry E. Steward
Donald Blevins	Clarie Dunbar	Robert Hopper	Maria Muraszkiwicz	Margaret Stewart
Chris Bomba	H. Allen Durkee	Marjorie C. Horton	Ellen Murphy	David Sucher
Joseph W. Brady	Rosemary Eaton	Cynthia Hunt Wilkinson	Edward Myers, Sr.	John H. Surridge
Marion Brady	Louis Ellis	Clete Idoux	Joseph Napoli	John Swan
George Breedlove	Mary Enterkin	Roberta Ingall	Dorothy Burke Odierna	Helga Switzler
Benjamin Brewster	Cyndy Escobar	Andrew Ingram	Alice Ondo	Martha Thomas
Philip J. Brown	Terrance Falk	L. Deane Jewell	Mel Paley	Mary Lou Thompson
Barry Brown	Antoinette Farmer	Eric Johnson	Beatrice Patti	James Tobey
Jesse Brown	Peter Farriher	Theresa Johnson	Craig Peffer	Irma Tureen
Monte Bryner	Joseph Ficarelli	Agnes Jordan	Adele Proom	Jeff Ureel
Julian E. Buchanan	Temple Ficklin	Earlene Stewart Kahanek	Ghobad Radbakht	Nicholas Vacc
Alma Buckley	Keith Fitzpatrick	Dan Kane	Kathy Rees	Jack Wagner
Patricia Burnett	Margaret Foley	Laurie Katz	Kendrick Reeves	Jay Waltz
Louise Bushnell	Steve Formica	Marian Kay	Christine Rich	Wilbur Walworth
Nicholas & June Camardello	Ann Francis	J.P. King	Giovanni Rizzacasa	Cindy Webb
Gordon Campbell	David Freed	Janet Kirkpatrick	Robbins	Cinda Weldon
Thomas Cantore	Janet Freedman	Anna Marie Klochak	Sarah Rosenthal	Cynthia Hunt Wilkinson
Janet Carlson	Carolyn Freeman	Trude Klugman	Donna Rousseau	Lucille Wink
Susan Casner	Mary Freeman	Thelma Kohler	Joyce Rumsey	Peter Wise
John Caulkins	Gerald Friedburg	Joseph M. Kopmeyer	Jean Sawyer	Francis X. Wright
Thurman Chambers	Ray Gamble	Gary LaFontaine	Howard Schimerling	Stephen Yates
James Chisholm	Marie Garratt	Herb Lange	Marcus Schwartz	Samuel Yohai
Lillian Chretien	Fernando Gaspar	James Laughlin	Joan Schwartz	David Young
Clifford Christensen	Margaret Gelchion	Irving Lebow	Jean Shapiro	Beth Young, Sr.
Virginia Cocannouer	Lorraine Gish	Tam Lodes	Sandra Shapiro	Selma Zuckerber
Marjorie Conley	Joseph Gistaro	Jack Lund	Mimi Sherry	
Gail Cook	Rachel Goforth	Marie Mabron	Sarah Shurkla	
Carol Lee Cordes	Mimi Gogos	Stuart MacMackin	Beverly Sichel	
Philomene Coughlin	Greg Goldberg	Jerry Maes	George Sichel	

Donors Continued from p. 12

Mark & Brenda Gordon	Evagelos Kavouriadis & Deborah Croland	William Meehan	Garry Rust	Nancy Vacc
Roland Goudreau	Cornelius Keating	Timothy Mehl	The Ryan Agency	Craig & Doris Vail
Grace Church Service League Ms. Betsy Leitch	William Keefe	Walter Mello	Jeffrey & Sonia Sachs	Joe Valenti
Paul & Priscilla Gray	John J. Keeley	Michael Agnello Jewlers	Saint Vincent Health Center	Valley Transporter, Inc.
Bruno Grayson	Walter Keeley	Chris & Barbara Michaels	G. West Saltonstall	Tony Vallone
James Greer II	James Keim Jr.	Paul & Susan Miller	Sand Dollar Foundation	John & Margaret Vandembossche
Grogan Graffam & McGinley	The Kerr Agency, Inc.	Stanley Miller Mr. & Mrs. Joep de Koning	Bill & Denise Schebil	Rob & Virginia Velger
George & Antonia Grumbach	Keystone Staffing	Jack Minner	Seaboard International Forest Products, Inc.	William Ventura
David & Mary Grumhaus	Kathy Kimball	Vin & Sharon Mollomo	Bob & Clare Sevenich	Julie Viscardi
Carl Haefling	Al Klugman	John Monninger	Seville Classics, Inc.	James T. Warzybok & Terri Wheeler
Arthur Haley Ms. Johanna Kozlowski	Abbas Kolahi	Bill & Margery Moore	Brad & Cynthia Shafer	Philip & Judith Webster
Haley Construction	Konell Insurance	Luke & Carol Moran	Thomas & Judith Shankie	Kathleen Weigand
Nicholas & Corelis Haliby	The Kooman Law Firm	Rick Morgan	Shepherd Insurance & Financial Services, Inc.	Eugene P. Weisser Jr. Insurance Agency
Terry Hamman	Michael J. Krahe	Stephen V. & Elizabeth Morgan	The Sherwood-Drolet Corp. Ltd.	Richard L. & Lois S. Werner
Law Offices of Walter J. Handelman	Christine Kumiega	Colleen Morrison	Lou & Sucheta Shoha	Amy Whipple
Harbortown Industries, Inc	L&S Food Sales Corp.	Duncan Moss & Nena Shaw	Lori Short	George & Betsy Whitehead
Mark & Kathleen Harrington	Lamp, O'Dell, Bartram, Levy & Trautwein	James & Patricia Mott	N. Shurkla	Roger & Susan Wit
Jan Harrison	Timothy & Barbara LaRouere	Jim Muir	Judith Siegel	Women Meeting Women
Victor & Marylou Harrold	Laskowski Insurance Agency	Evelyn Mulso	Bill & Linda Musser	Wyndham International
Walter Hatfield	Law Offices Cattel, Tuyn & Rudzewicz	Bill & Linda Musser	Maury Myers	SIL, INC.
Blair Heavey	Sandra Leathley	Maury Myers	NAT Properties	Linda Simpson
Will Heespelink	Sharon LeClair	Norman Nadalin	Warren & Flo Sinsheimer	Warren & Flo Sinsheimer
Harold & Sonny Helmkampf	Charles G. Leon III	Timothy NeCastro	John Siragusa	John Siragusa
Greg & Christine Henk	Peter Levin	Ofer & Shelly Nemirovsky	Timothy NeCastro	Alicia Skodol
James Heywood	Wilbur & Phyllis Levin	Allie Nield	Kathryn Sloan	Michael Slogan
John & Peggy Heywood	Liberty Mutual	NMS Communications	Michael Slogan	Roger Smith
Stephen Heywood	Claude Lilly	NOVA Coffee House	Roger Smith	Smith Family
John & Julie Hice	Joseph Lo Cicero	Danny Nowicki	George Snell	Eric W. Snyder
Timothy Hillman	William Lockeretz & Sarah Wernick	Michael O'Connell	Eric W. Snyder	Mark & Mary Sobeck
Hitchcock-Brenner Insurance Company	Jack & Marion Longwell	Patrick & Nancy O'Connor	Mark & Mary Sobeck	Mark E. Sommer & Ellen J. Baker
House of Floors North, Inc.	John & Kathy Lopez	Patrick D. & Mary O'Connor	Mark E. Sommer & Ellen J. Baker	James Sorbara
Matt Housley	Gerard LoPorto	S. O'Sullivan UFG428	James Sorbara	Jim & Kelly Spagnuolo
David & Betsy Hughes	Los Angeles Community College District	Gary & Rita Oravitz	Jim & Kelly Spagnuolo	Spalding Family Foundation
Jeff Hughes	Karen Loud	Virginia Palazzo	Spalding Family Foundation	James & Mary Spaulding
Russell Hughey	Louis Pratt Insurance Agency	Maryann Parker	James & Mary Spaulding	Alan & Roz Spier
Doug & Natalie Hugo	The Iowa Group, Inc.	John & Patricia Pasquinelli	Alan & Roz Spier	Marc & Mimi Spier
Elizabeth Hylton	Bob & Cyndee Luedeking	David & Maria Patterson	Marc & Mimi Spier	Patrick Spratt
Rick & Connie Iceberg	Luxenberg, Garbett, Kelly & George, P.C.	John & Linda Patterson	Patrick Spratt	Chuck & Karen Spriggs
Vincent J. Indorato Jr.	John & Gail MacArthur	Patterson Brothers Painting, Inc.	Chuck & Karen Spriggs	St. Hugo of the Hills Church
Industrial Sales & Mfg. Inc.	Norman Mack	Christopher Pazoles	St. Hugo of the Hills Church	Harry & Elyn Steinbok
J. Alan Inglis	Scott J. MacPherson	James Perry	Harry & Elyn Steinbok	Dee Stemrich
Alan G. Inglis & Sally Scripture	Robert S. Madia	PIA Services, Inc.	Dee Stemrich	Lynn Stern & Jeremy Lang
Insource Services, Inc.	Donald Mahaney	John Piantedosi	Lynn Stern & Jeremy Lang	Thayer Stewart
Insurance Institute for Highway Safety	Timothy Maher	Robert & Cynthia Pill	Thayer Stewart	Elizabeth Stoddard
INvision Consulting Services	Ted & Janet Makowski	Pioneer Valley Legal Associates, LLP	Elizabeth Stoddard	John F. Sullivan
Larry & Mary Isaacs	Reed Maltzman	Larry & Susan Piper	John F. Sullivan	R. Thomas Swem
Italian American War Veterans of USA	Maritz Research	Larry Plutnicki	R. Thomas Swem	Bradford & Holly Swett
Jack Martin Insurance Group	Marshalls/TJ Maxx	Joseph Polito	Bradford & Holly Swett	Bernadette LaLonde Tayler
Doug & Michelle Jacoby	Sarah S. Martin	J. Brian & Catherine Potts	Bernadette LaLonde Tayler	Tele-Review LLC
Martin & Marjory Jaffe	Mark Mattheus	Dick & Gail Poulsen	Tele-Review LLC	Richard Terrio
James Murray Insurance	The Math Works, Inc.	PPM Consulting	Richard Terrio	David & Heather Thomas
JEM Electronics, Inc.	Mary Anne Mauriello Le Viet	Ernie & Margaret Prisbe	David & Heather Thomas	Rodney Thomas
Jewish Communal Fund	Kathleen McAllister	Heather Purvis	Rodney Thomas	Susan Thomas
John Hancock Financial Services, Inc.	Jim & Sally McAlpine	Regina Rear	Susan Thomas	Thomas A. Nolfi, Inc.
Keith Johnson	Mark McArdle	Bob Regener	Thomas A. Nolfi, Inc.	Wendl Thomis & Rose Ann Giordano
Joli Day Spa	John S. McDonald	Stan & Bobbi Rice	Wendl Thomis & Rose Ann Giordano	Kevin & Karen Till
Jeffery Jones	McDonald Ford	Charles Rizzo	Kevin & Karen Till	Robert Timpson Jr.
Jonathan Joseph & Lynne Esselstein	McElhinny Insurance Agency	The Robbins Family Foundation, Inc.	Robert Timpson Jr.	Total Logistic Control, LLC
Jon Kappelson	McGreevy Insurance Agency, Inc.	James R. Roehm	Total Logistic Control, LLC	Chuck & Jill Turnbull
Karoun Inc.	Jack & Geri McNulty	Charlie & Elaine Romeo	Chuck & Jill Turnbull	The United Way of Erie County
Kattan-Ferretti Insurance Agency, Inc.	McQuaid Jesuit High School	Eric D. Root	The United Way of Erie County	Daniel Ureel
	Louis & Jill Behr Medved	Andrew Rosenthal	Daniel Ureel	Donald & Thelma Ureel
		Edward & Martha Rosenthal	Donald & Thelma Ureel	Mike & Betsy Useem
		John Rudzewicz	Mike & Betsy Useem	
		Bob Russell		

Special Vendors

ALSTDF thanks the following companies and people for enabling us to spend more on drug discovery and less on operational costs through offering reduced rates and continued support.

- Bobby Oommen
- Citymail
- Corporate Limelight, Inc.
- Greg Gonyea
- Hamilton Hughes Design
- Jackson Laboratories
- Interaction Institute
- Mister Reusch
- OPS Printing
- Richard Howard Photography
- United Lithograph